Melanoma News and Research

Latest Melanoma News and Research

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib.

23 Jul 2015

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center is ranked among the top 10 cancer centers in the nation, according to a U.S. News & World Report survey of board-certified physicians from across the country. The survey reviewed patient outcomes, the cancer center's reputation among physicians, mortality rates and other care-related factors.

22 Jul 2015

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA.

22 Jul 2015

GUMC physician leads new national clinical trial for melanoma treatment

A Georgetown University Medical Center physician renowned for his research in melanoma will lead a new national clinical trial involving novel treatments for the disease. The study compares the sequencing of two groups of drugs -- both effective in treating melanoma.

22 Jul 2015

New phase III cancer treatment trial opens for patient with advanced melanoma

A new phase III cancer treatment trial has opened for patient enrollment that examines two treatments that work in completely different ways yet have both been shown in previous clinical trials to be effective in treating patients with advanced melanoma, the ECOG-ACRIN Cancer Research Group announced today.

22 Jul 2015

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced today that the U.S. Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma.

20 Jul 2015

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions.

20 Jul 2015

BUSM investigators receive MRA's Jackie King Young Investigator Awards

Boston University School of Medicine researchers Neil Joseph Ganem, PhD and Anurag Singh, PhD, each have received the Jackie King Young Investigator Awards from the Melanoma Research Alliance (MRA), the largest private funder of melanoma research. Both serve as assistant professors of pharmacology & experimental therapeutics and medicine.

17 Jul 2015

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.

16 Jul 2015

Immunocore completes $320 million (£205 million) private financing round

Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round.

16 Jul 2015

Noninvasive prenatal screening could detect maternal cancer

A study published today in the Journal of the American Medical Association shows that genetic test results, as revealed by non-invasive prenatal testing for fetal chromosome abnormalities, may detect underlying conditions in the mother, including cancer.

15 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the US National Cancer Institute, a world-leading institute for cancer research, today announced that they have implemented two-way linking between research articles on ScienceDirect and datasets stored in NCI's cancer Nanotechnology Laboratory (caNanoLab) data portal.

9 Jul 2015

Huntsman Cancer Institute receives NCI's Comprehensive Cancer Center designation

The National Cancer Institute has awarded Huntsman Cancer Institute at the University of Utah its Comprehensive Cancer Center status, the highest designation possible.

9 Jul 2015

ImmunID announces publication of clinical study data on ImmunTraCkeR assay in the Journal for ImmunoTherapy of Cancer

ImmunID today announced the publication of a short report in the Journal for ImmunoTherapy of Cancer showing that the analysis of peripheral T cell receptor diversity using the company's ImmunTraCkeR assay is associated with clinical outcomes following Ipilimumab treatment in metastatic melanoma.

8 Jul 2015

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy (ipilumumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor.

8 Jul 2015

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

T cells from patients with melanoma can trigger a protective immune response against the disease according to a new study out of University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine.

8 Jul 2015

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.

2 Jul 2015

Study finds link between citrus fruit consumption and melanoma risk

A new analysis of two long-term studies has revealed a potential association between malignant melanoma risk and frequent consumption of grapefruit and oranges. The study found that compared with people who consumed these fruits less than twice a week, those who had them at least 1.6 times a day were at a 36% higher risk of developing melanoma.

2 Jul 2015

Melanoma News and Research

Latest Melanoma News and Research

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

GUMC physician leads new national clinical trial for melanoma treatment

New phase III cancer treatment trial opens for patient with advanced melanoma

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

NeoGenomics announces launch of new germline cancer predisposition testing services

BUSM investigators receive MRA's Jackie King Young Investigator Awards

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Immunocore completes $320 million (£205 million) private financing round

Noninvasive prenatal screening could detect maternal cancer

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Huntsman Cancer Institute receives NCI's Comprehensive Cancer Center designation

ImmunID announces publication of clinical study data on ImmunTraCkeR assay in the Journal for ImmunoTherapy of Cancer

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Study finds link between citrus fruit consumption and melanoma risk

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in